Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
If your plan covers Ozempic or Wegovy for obesity (BMI 30+) or overweight with comorbidities (BMI 27+), your provider can submit the prescription under the weight management indication instead
Two reviewers independently screened titles and abstracts to determine eligibility
Hospitals manage approximately 58% of complex metabolic cases, where dosage adjustments and combination therapies are required
Given the importance of identifying new therapies for BED and the promising outcomes associated with GLP-1 receptor agonists, this article systematically reviews the effects of these drugs on BED, with a specific focus on their impact on anthropometric variables
The FDA approved semaglutide and tirzepatide for treatment of type 2 diabetes and obesity
